<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01076660</url>
  </required_header>
  <id_info>
    <org_study_id>Reynolds03073103</org_study_id>
    <nct_id>NCT01076660</nct_id>
  </id_info>
  <brief_title>Left Ventricular Structural Predictors of Sudden Cardiac Death</brief_title>
  <official_title>Left Ventricular Structural Predictors of Sudden Cardiac Death [Substudy of: Functional Energetics and Imaging for Phenotypic Characterization of Patients at Risk for Sudden Cardiac Death, See Also NCT000181233]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Donald W. Reynolds Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Christiana Care Health Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sudden cardiac death (SCD) poses a significant health care challenge with high annual
      incidence and low survival rates. Implantable cardioverter defibrillators (ICDs) prevent SCD
      in patients with poor heart function. However, the critical survival benefit afforded by the
      devices is accompanied by short and long-term complications and a high economic burden.
      Moreover, in using current practice guidelines of reduced heart function, specifically left
      ventricular ejection fraction (LVEF)≤35%, as the main determining factor for patient
      selection, only a minority of patients actually benefit from ICD therapy (&lt;25% in 5 years).
      There is an essential need for more robust diagnostic approaches to SCD risk stratification.

      This project examines the hypothesis that structural abnormalities of the heart itself, above
      and beyond global LV dysfunction, are important predictors of SCD risk since they indicate
      the presence of the abnormal tissue substrate required for the abnormal electrical circuits
      and heart rhythms that actually lead to SCD. Information about the heart's structure will be
      obtained from cardiac magnetic resonance imaging and used in combination with a number of
      other clinical risk factors to see if certain characteristics can better predict patients at
      risk for SCD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sudden cardiac death (SCD) poses a significant health care challenge with high annual
      incidence and low survival rates. Implantable cardioverter defibrillators (ICDs) prevent SCD
      in patients with left ventricular (LV) systolic dysfunction. However, the critical survival
      benefit afforded by the devices is accompanied by short and long-term complications and a
      high economic burden. Moreover, in using current practice guidelines of LV ejection fraction
      (LVEF)≤35% as the main determining factor for patient selection, only a minority of patients
      actually benefit from ICD therapy (&lt;25% in 5 years). There is an essential need for more
      robust diagnostic approaches to SCD risk stratification.

      This project examines the hypothesis that LV structural abnormalities above and beyond global
      LV dysfunction are important predictors of SCD risk since they indicate the presence of
      abnormal pathophysiologic substrate required for the ventricular arrhythmogenicity leading to
      SCD. This premise is supported by pre-clinical models and limited patient cohort studies
      examining the contribution of individual LV structural indices. However, there has been no
      prospective study of primary prevention ICD candidates in sufficiently large numbers to
      investigate the incremental value of a comprehensive assessment of LV structure on SCD risk
      over and above that of LVEF and readily available demographic and clinical variables.

      LV structure can be quantified in detail using cardiac magnetic resonance imaging with late
      gadolinium enhancement (CMR-LGE). Specifically, accurate assessment of global LV function,
      volumes, mass, geometry, and infarct/scar characteristics are feasible and obtainable
      clinically in a single examination. We aim to examine whether or not any of these CMR indices
      or combination of indices are better able to discriminate between patients with high versus
      low susceptibility to SCD within the broader population of reduced LVEF patients. If the
      results of these studies demonstrate that LV structure is an important prognostic risk
      factor, it may be then be possible to more specifically focus ICD therapy to those who are
      most likely to benefit and avoid unnecessary device implantations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite SCD outcomes</measure>
    <time_frame>Every 6 months for 5 years</time_frame>
    <description>The first occurrence of an adjudicated appropriate ICD firing for ventricular tachycardia/ventricular fibrillation or cardiac death not treated by the ICD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite cardiac outcomes</measure>
    <time_frame>Every 6 months for 5 years</time_frame>
    <description>The first occurrence of an adjudicated appropriate ICD firing for ventricular tachycardia/ventricular fibrillation, hospitalization for heart failure or cardiac death.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Ischemic Cardiomyopathy</condition>
  <condition>Nonischemic Cardiomyopathy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with LV ejection fraction (LVEF) ≤35% of ischemic or nonischemic etiology (as
        measured by a clinical echocardiogram, ventriculogram, or radionuclide study) referred
        clinically for ICD insertion for primary prevention purposes (i.e. no prior history of
        sustained ventricular arrhythmias)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LVEF≤35%, referred clinically for ICD insertion for primary prevention purposes (i.e.
             no prior history of sustained ventricular arrhythmias)

          -  Between the ages of 21 and 80 years old

          -  Permission of the patient's clinical attending physician

        Exclusion Criteria:

          -  Patients who refuse or are unable to give consent.

          -  Individuals with contraindications to MRI (i.e. implanted metallic objects such as
             pre-existing cardiac pacemakers, cerebral clips or indwelling metallic projectiles)

          -  Minors.

          -  Pregnant women.

          -  NYHA Class IV heart failure.

          -  Chronic renal insufficiency with creatinine clearance&lt;60 ml/min; acute renal
             insufficiency of any severity

          -  Claustrophobia

          -  Prior adverse reaction to gadolinium-based contrast
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert G Weiss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeannette Walker, RN</last_name>
    <phone>410-502-7310</phone>
    <email>jhoefli1@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medical Institutions</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Katherine Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Schmidt A, Azevedo CF, Cheng A, Gupta SN, Bluemke DA, Foo TK, Gerstenblith G, Weiss RG, Marbán E, Tomaselli GF, Lima JA, Wu KC. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation. 2007 Apr 17;115(15):2006-14. Epub 2007 Mar 26.</citation>
    <PMID>17389270</PMID>
  </results_reference>
  <results_reference>
    <citation>Fernandes VR, Wu KC, Rosen BD, Schmidt A, Lardo AC, Osman N, Halperin HR, Tomaselli G, Berger R, Bluemke DA, Marbán E, Lima JA. Enhanced infarct border zone function and altered mechanical activation predict inducibility of monomorphic ventricular tachycardia in patients with ischemic cardiomyopathy. Radiology. 2007 Dec;245(3):712-9. Epub 2007 Oct 2.</citation>
    <PMID>17911537</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, Dalal D, Lai S, Bluemke DA, Gerstenblith G, Marbán E, Tomaselli GF, Lima JA. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008 Jun 24;51(25):2414-21. doi: 10.1016/j.jacc.2008.03.018.</citation>
    <PMID>18565399</PMID>
  </results_reference>
  <results_reference>
    <citation>Ouwerkerk R, Bottomley PA, Solaiyappan M, Spooner AE, Tomaselli GF, Wu KC, Weiss RG. Tissue sodium concentration in myocardial infarction in humans: a quantitative 23Na MR imaging study. Radiology. 2008 Jul;248(1):88-96. doi: 10.1148/radiol.2481071027.</citation>
    <PMID>18566171</PMID>
  </results_reference>
  <results_reference>
    <citation>Ardekani S, Weiss RG, Lardo AC, George RT, Lima JA, Wu KC, Miller MI, Winslow RL, Younes L. Computational method for identifying and quantifying shape features of human left ventricular remodeling. Ann Biomed Eng. 2009 Jun;37(6):1043-54. doi: 10.1007/s10439-009-9677-2. Epub 2009 Mar 26.</citation>
    <PMID>19322659</PMID>
  </results_reference>
  <results_reference>
    <citation>Bottomley PA, Wu KC, Gerstenblith G, Schulman SP, Steinberg A, Weiss RG. Reduced myocardial creatine kinase flux in human myocardial infarction: an in vivo phosphorus magnetic resonance spectroscopy study. Circulation. 2009 Apr 14;119(14):1918-24. doi: 10.1161/CIRCULATIONAHA.108.823187. Epub 2009 Mar 30.</citation>
    <PMID>19332463</PMID>
  </results_reference>
  <results_reference>
    <citation>Strauss DG, Selvester RH, Lima JA, Arheden H, Miller JM, Gerstenblith G, Marbán E, Weiss RG, Tomaselli GF, Wagner GS, Wu KC. ECG quantification of myocardial scar in cardiomyopathy patients with or without conduction defects: correlation with cardiac magnetic resonance and arrhythmogenesis. Circ Arrhythm Electrophysiol. 2008 Dec;1(5):327-36. doi: 10.1161/CIRCEP.108.798660. Epub 2008 Dec 2.</citation>
    <PMID>19808427</PMID>
  </results_reference>
  <results_reference>
    <citation>Strauss DG, Wu KC. Imaging myocardial scar and arrhythmic risk prediction--a role for the electrocardiogram? J Electrocardiol. 2009 Mar-Apr;42(2):138.e1-8. doi: 10.1016/j.jelectrocard.2008.12.010. Epub 2009 Jan 30. Review.</citation>
    <PMID>19185315</PMID>
  </results_reference>
  <results_reference>
    <citation>Arevalo HJ, Vadakkumpadan F, Guallar E, Jebb A, Malamas P, Wu KC, Trayanova NA. Arrhythmia risk stratification of patients after myocardial infarction using personalized heart models. Nat Commun. 2016 May 10;7:11437. doi: 10.1038/ncomms11437.</citation>
    <PMID>27164184</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang Y, Guallar E, Weiss RG, Stillabower M, Gerstenblith G, Tomaselli GF, Wu KC. Associations between scar characteristics by cardiac magnetic resonance and changes in left ventricular ejection fraction in primary prevention defibrillator recipients. Heart Rhythm. 2016 Aug;13(8):1661-6. doi: 10.1016/j.hrthm.2016.04.013. Epub 2016 Apr 19.</citation>
    <PMID>27108939</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu KC, Gerstenblith G, Guallar E, Marine JE, Dalal D, Cheng A, Marbán E, Lima JA, Tomaselli GF, Weiss RG. Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death. Circ Cardiovasc Imaging. 2012 Mar;5(2):178-86. doi: 10.1161/CIRCIMAGING.111.968024. Epub 2012 Jan 20.</citation>
    <PMID>22267750</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>February 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2010</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic cardiomyopathy</keyword>
  <keyword>Nonischemic cardiomyopathy</keyword>
  <keyword>Implantable cardioverter defibrillator</keyword>
  <keyword>Sudden Cardiac Death</keyword>
  <keyword>Ventricular tachycardia</keyword>
  <keyword>Ventricular fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Death</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

